Phase III randomized study of vinorelbine (V), gemcitabine (G) followed by docetaxel (D) (VGD) versus paclitaxel (P) and carboplatin (C) (PC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) (Japan Multinational Trial Organization LC00-03)

Masaaki Kawahara,Mitsumasa Ogawara,Yutaka Nishiwaki,Kaoru Kubota,Kiyoshi Komuta,Koichi Minato,Y. Fujita,Hideki Origasa,Masanori Fukushima,Kiyoyuki Furuse

Phase III randomized study of vinorelbine (V), gemcitabine (G) followed by docetaxel (D) (VGD) versus paclitaxel (P) and carboplatin (C) (PC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) (Japan Multinational Trial Organization LC00-03)

2006

Masaaki Kawahara
Mitsumasa Ogawara
Yutaka Nishiwaki
Kaoru Kubota
Kiyoshi Komuta
Koichi Minato
Y. Fujita
Hideki Origasa
Masanori Fukushima
Kiyoyuki Furuse

7013 Background: Our phase II study of non-platinum VGD for advanced NSCLC demonstrated excellent results with the median survival time (MST) of 15.7 mos and a 1-year survival rate of 59% (Brit J C...

Keywords:

non-small cell lung cancer (NSCLC)
Randomized controlled trial
Carboplatin
Gemcitabine
Vinorelbine
Cancer research
Paclitaxel
Oncology
Internal medicine
Medicine
Docetaxel
Phases of clinical research
Survival rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations